Drug Trial Radar · NCT02664935
National Lung Matrix Trial: Multi-drug Phase II Trial in Non-Small Cell Lung Cancer
Last checked: Nov 19, 2026Latest source record: Apr 28, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
423
Actual
Start
May 13, 2015
Primary completion
Nov 29, 2023
Study completion Nov 29, 2023
Sponsor
- Lead sponsor
- University of BirminghamAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Cancer Research UK; AstraZeneca; Pfizer; Experimental Cancer Medicine Centres; Mirati Therapeutics Inc.
- First posted
- Jan 27, 2016
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The trial consists of a series of parallel multi-centre single arm phase II trial arms, each testing an experimental targeted drug in a population stratified by multiple pre-specified actionable target putative biomarkers. The primary objective is to evaluate whether there is a signal of activity in each drug-(putative)biomarker cohort separately. A Bayesian adaptive design is adopted to achieve this objective and statistical details are given in the Protocol.
Conditions
- Non-Small Cell Lung Cancer
- Carcinoma, Squamous Cell
- Adenocarcinoma
Interventions
AZD4547Drug
FGFR Inhibitor
VistusertibDrug
MTORC1/2 Inhibitor
PalbociclibDrug
CDK4/6 Inhibitor
CrizotinibDrug
ALK/MET/ROS1 Inhibitor
SelumetinibDrug
MEK Inhibitor
DocetaxelDrug
Taxane, anti-mitotic cytotoxic chemotherapy
AZD5363Drug
AKT Inhibitor
OsimertinibDrug
EGFRm+ T790M+ Inhibitor
DurvalumabDrug
Anti-PDL1
SitravatinibDrug
VEGFR Inhibitor
AZD6738Drug
ATR inhibitor
Primary outcomes
What the sponsor says the trial is designed to measure.
- Objective response (OR)Time frame: From baseline until disease progression, assessed up to 18 months.
- Progression-free survival time (PFS)Time frame: From date of commencement of trial treatment to date of CT scan when progressive disease first recorded or date of death without previously recorded progression, assessed up to 18 months.
- Durable clinical benefit (DCB)Time frame: From baseline until the first scan after 24 weeks showing the patient free of disease progression.
Locations
25 sites in 1 country. Site status is shown where the registry gives one.
Aberdeen Royal Infirmary
Aberdeen, United Kingdom
Belfast City Hospital, Belfast Health and Social Care Trust
Belfast, United Kingdom
Queen Elizabeth Hospital Birmingham, University Hospitals Birmingham NHS Foundation Trust
Birmingham, United Kingdom
Birmingham Heartlands Hospital, Heart of England NHS Foundation Trust
Birmingham, United Kingdom
University Hospitals Bristol NHS Foundation Trust
Bristol, United Kingdom
Addenbrooke's Hospital, Cambridge University Hospitals NHS Foundation Trust
Cambridge, United Kingdom
Velindre Cancer Centre, Velindre NHS Trust
Cardiff, United Kingdom
Colchester General Hospital
Colchester, United Kingdom
Edinburgh Cancer Centre, Western General Hospital
Edinburgh, United Kingdom
Royal Devon and Exeter Hospital
Exeter, United Kingdom
Beatson West of Scotland Cancer Centre
Glasgow, United Kingdom
St. James' University Hospital, Leeds Teaching Hospital NHS Trust
Leeds, United Kingdom
Leicester Royal Infirmary, University Hospitals of Leicester NHS Trust
Leicester, United Kingdom
Royal Marsden Hospital, The Royal Marsden NHS Foundation Trust
London, United Kingdom
Charing Cross Hospital, Imperial College Healthcare NHS Trust
London, United Kingdom
Guy's Hospital, Guy's and St Thomas' NHS Foundation Trust
London, United Kingdom
St Bartholomew's Hospital, Barts Health NHS Trust
London, United Kingdom
University College Hospital, University College London Hospitals NHS Foundation Trust
London, United Kingdom
Maidstone Hospital
Maidstone, United Kingdom
The Christie Hospital, The Christie NHS Foundation Trust
Manchester, United Kingdom
Clatterbridge Cancer Centre
Metropolitan Borough of Wirral, United Kingdom
Sir Bobby Robson Cancer Trial Research Centre, The Newcastle upon Tyne Hospitals
Newcastle, United Kingdom
Churchill Hospital, Oxford University Hospitals NHS Foundation Trust
Oxford, United Kingdom
Weston Park Hospital, Sheffield Teaching Hospitals NHS Foundation Trust
Sheffield, United Kingdom
Southampton General Hospital, University Hospital Southampton NHS Foundation Trust
Southampton, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.